Navigation Links
Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year

INDIANAPOLIS, Oct. 1, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that applications for the 2014-2015 school year are now available for the 16th annual Lilly Reintegration Scholarship.  Since its inception, the program has directed more than four million dollars in tuition, books and laboratory fees to hundreds of colleges, trade and vocational schools and high school equivalency programs across the United States to fund educational pursuits of students living with bipolar disorder, schizophrenia or schizo-affective disorder. This year the program expands to include the diagnosis of major depressive disorder. Further information is available at

"Our goal when the program was established in 1997 was to demonstrate that when proper community resources are in place, individuals battling mental illness can reintegrate into society," explained Robert Baker, M.D., vice president, global medical affairs, Lilly Bio-Medicines.  "Based upon graduation rates today, it is clear that these dedicated students are achieving well beyond preliminary program goals. They are excelling in the classroom and predominantly graduating with honors.  As part of our continuing commitment to the neuroscience community, we are pleased to expand the program to include students living with major depressive disorder."

Lilly Reintegration Scholarship students have pursued their educational goals at the University of Chicago, Massachusetts Institute of Technology and Stanford University, to name a few, as well as at more than three hundred state and private universities, community colleges and trade schools. Recent areas of study include architecture, business administration, medical lab technology, animation arts and cosmetology. An independent judging panel comprised of psychiatric care professionals review applications annually and select scholarship recipients.

"We are proud to expand the program to include students living with major depressive disorder," said Ralph Aquila, M.D., executive director of the Center for Reintegration and chairman of the Lilly Reintegration Scholarship judging panel. "More than fourteen million Americans live with major depression. They often times have difficulty performing the routine activities of daily life and experience social isolation; many are even hospitalized. We hope this program will be a source of inspiration for these students as well."

Dr. Aquila explained that after reviewing the success rate of past program participants, and seeing that their graduation rate is higher than the national average – 71 percent vs. 55.5 percent[i] – it was agreed that the program should expand the range to assist more students. "This is not like most other scholarships, as we work with each student's individual needs and we advocate for them," he noted. "When you are a Lilly Reintegration Scholar, you are not alone. You have the entire judging panel's faith in your abilities."

About the Lilly Reintegration Scholarship

The goal of the Lilly Reintegration Scholarship is to help people with schizophrenia, schizo-affective disorder, bipolar disorder or major depressive disorder acquire the educational and vocational skills necessary to reintegrate into society, secure jobs and to improve  their lives. Through the program, Eli Lilly and Company furthers its ongoing commitment to providing tools that enhance the reintegration continuum, allowing people to move their lives forward and achieve their individual potential. Further information is available at

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at  


[i] According to the National Center for Higher Education Management Systems:  

Refer to:
Stephanie Libous (RF|Binder), +1(212) 994-7588, 
Morry Smulevitz (Lilly), +1(317) 651-5567, 

(Logo: )

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
2. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
5. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
6. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
7. Dr. Marschall S. Runge Elected to Lilly Board of Directors
8. Lilly Reports Second-Quarter 2013 Results
9. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
10. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
11. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family ... tests directly from their electronic medical record (EMR) without the need for redundant ...
(Date:11/26/2015)... ... 2015 , ... Jobs in hospital medical laboratories and in the imaging field ... agency Aureus Medical Group . These fields, as well as travel ... for healthcare jobs through the company’s website, , The leading healthcare ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
Breaking Medicine News(10 mins):